Based on this, the researchers found that splicing inhibitors can sensitize multiple myeloma cells to venetoclax through its affection on MCL-1 transcripts, shifting cells from MCL-1-dependent to BCL-2-dependent (103). The gene discussed is MCL1; the disease is plasma cell myeloma.